Plant Name: Passiflora edulis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NPSR1; | |
| ADORA3; ADORA2A; ADORA1; | |
| RECQL; TDP1; ADK; PKM; GLO1; ALOX12; HSD17B1; AKR1B1; HSD17B10; ALOX15; NOX4; USP2; TNKS; PARP1; TNKS2; POLB; CD38; | |
| ACHE; | |
| CFTR; | |
| GSK3B; SYK; FLT3; DYRK2; CDK6; CSNK2A1; HASPIN; | |
| CA2; CA12; CA7; CA4; | |
| AR; | |
| ESR2; ESR1; | |
| ALOX5; MAOA; PTGS2; XDH; | |
| KDM4E; | |
| MMP9; MMP12; MMP2; | |
| HIF1A; TP53; NFKB1; STAT6; | |
| KMT2A; | |
| ABCG2; ABCC1; | |
| SLC28A2; SLC28A1; SLC28A3; | |
| NPC1; LMNA; TTR; MAPT; THPO; APP; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | DYRK2 | Dual-specificity tyrosine-phosphorylation regulated kinase 2 | Q92630 | CHEMBL4376 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | HASPIN | Serine/threonine-protein kinase haspin | Q8TF76 | CHEMBL1075163 |
| SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.219E-10 | 1.154E-07 | ADORA1, ADORA2A, CA2, CA7, CD38, CDK6, CFTR, HIF1A, NPC1, NPSR1, PARP1, PTGS2, SYK, TNKS, TNKS2 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.750E-10 | 1.465E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.454E-10 | 1.909E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4, NOX4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.966E-10 | 2.153E-07 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4, XDH |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 5.206E-10 | 3.239E-07 | ADORA2A, CA2, CA7, CFTR, HIF1A, NPC1, NPSR1, PTGS2, SYK, TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 6.341E-09 | 2.466E-06 | ABCG2, ACHE, ADORA2A, APP, CD38, CSNK2A1, ESR1, ESR2, FLT3, KMT2A, MAPT, MMP9, NFKB1, PARP1, PKM, PTGS2, SMN1, SMN2, STAT6, TP53, TTR, USP2, XDH |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.995E-08 | 6.788E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4, NOX4, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 8.536E-08 | 2.239E-05 | ABCC1, ALOX12, ALOX15, ALOX5, SYK |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.681E-07 | 4.161E-05 | AR, CA12, CA2, CA4, CA7, ESR1, ESR2, GLO1, KMT2A, MMP12, MMP2, MMP9, PARP1, TNKS, TP53 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.094E-07 | 5.012E-05 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 2.785E-07 | 6.317E-05 | ALOX12, ALOX15, ALOX5, PTGS2 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.260E-07 | 1.041E-04 | CA12, CA2, CA4, CA7, CFTR |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 6.812E-07 | 1.336E-04 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1 |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 8.396E-07 | 1.594E-04 | AR, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 9.045E-07 | 1.683E-04 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 1.253E-06 | 2.200E-04 | ADORA1, ADORA2A, ADORA3, APP, AR, CDK6, CYP1B1, KMT2A, LMNA, NOX4, PTGS2, TP53, XDH |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 1.579E-06 | 2.491E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0008152; metabolic process | GO:0031328; positive regulation of cellular biosynthetic process | 3.199E-06 | 4.583E-04 | ADORA2A, APP, AR, CD38, DYRK2, ESR1, ESR2, HIF1A, KMT2A, MMP12, NFKB1, NOX4, PARP1, PTGS2, STAT6, SYK, TNKS, TNKS2, TP53, TSHR |
| BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 3.769E-06 | 5.162E-04 | ADORA2A, APP, MAPT |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 3.769E-06 | 5.162E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 5.371E-06 | 6.839E-04 | CA2, CA7, CFTR |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 5.371E-06 | 6.839E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 7.366E-06 | 9.061E-04 | AR, CYP19A1, ESR1 |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 8.058E-06 | 9.802E-04 | AKR1B1, CDK6, CFTR, CYP1B1, NFKB1, PTGS2, STAT6, TP53 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 8.534E-06 | 1.027E-03 | CA12, CA2, CA4, CA7 |
| BP | GO:0065007; biological regulation | GO:0044093; positive regulation of molecular function | 9.564E-06 | 1.132E-03 | ADORA1, APP, AR, CFTR, ESR1, ESR2, FLT3, GSK3B, HIF1A, KMT2A, MAPT, MMP9, NFKB1, NOX4, PARP1, SYK, TNKS, TSHR, XDH |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 9.795E-06 | 1.153E-03 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 1.270E-05 | 1.424E-03 | ADORA2A, CA2, CA7 |
| BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 1.295E-05 | 1.424E-03 | SLC28A2, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.295E-05 | 1.424E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.295E-05 | 1.424E-03 | ESR1, ESR2 |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 1.295E-05 | 1.424E-03 | SLC28A1, SLC28A3 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.295E-05 | 1.424E-03 | ALOX12, ALOX15 |
| MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 1.295E-05 | 1.424E-03 | SLC28A2, SLC28A3 |
| BP | GO:0050896; response to stimulus | GO:0048545; response to steroid hormone | 1.431E-05 | 1.550E-03 | AR, CA2, CD38, FLT3, NPC1, PARP1, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0014074; response to purine-containing compound | 1.481E-05 | 1.597E-03 | ADORA2A, APP, CFTR, NOX4, PTGS2, TP53 |
| BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 1.853E-05 | 1.940E-03 | ABCG2, APP, CA12, CA2, CA7, CD38, CFTR, ESR1, HIF1A, NPSR1, TP53 |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 1.871E-05 | 1.940E-03 | MAPT, NOX4, PTGS2, TP53, XDH |
| BP | GO:0065007; biological regulation | GO:0048167; regulation of synaptic plasticity | 2.005E-05 | 2.060E-03 | ADORA1, ADORA2A, APP, CD38, KMT2A, PTGS2 |
| BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 2.255E-05 | 2.283E-03 | ACHE, ADORA2A, CD38, CFTR, HIF1A, MMP12, SYK |
| CC | GO:0044464; cell part | GO:0030673; axolemma | 2.468E-05 | 2.488E-03 | ADORA1, ADORA2A, MAPT |
| BP | GO:0050896; response to stimulus | GO:0032870; cellular response to hormone stimulus | 3.300E-05 | 3.193E-03 | AR, ESR1, FLT3, NFKB1, NPC1, PARP1, PKM, TSHR |
| BP | GO:0008152; metabolic process | GO:0031324; negative regulation of cellular metabolic process | 3.643E-05 | 3.449E-03 | ADORA2A, APP, AR, CD38, CSNK2A1, CYP2D6, ESR1, ESR2, GSK3B, HIF1A, MAPT, MMP12, MMP9, NFKB1, NPC1, PARP1, PTGS2, STAT6, TNKS, TNKS2, TP53, USP2, XDH |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 3.875E-05 | 3.486E-03 | SLC28A1, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 3.875E-05 | 3.486E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.875E-05 | 3.486E-03 | CA2, CA7 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 3.875E-05 | 3.486E-03 | SLC28A1, SLC28A3 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 3.875E-05 | 3.486E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 3.875E-05 | 3.486E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 3.875E-05 | 3.486E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 3.875E-05 | 3.486E-03 | ALOX12, ALOX15 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 3.875E-05 | 3.486E-03 | ADORA1, ADORA2A |
| BP | GO:0065007; biological regulation | GO:0050790; regulation of catalytic activity | 4.169E-05 | 3.736E-03 | ADORA1, ADORA2A, ADORA3, APP, AR, CSNK2A1, ESR1, FLT3, GSK3B, HIF1A, MAPT, MMP9, NFKB1, NOX4, PARP1, PTGS2, SYK, TNKS, TP53, TSHR, XDH |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 4.362E-05 | 3.861E-03 | NOX4, PARP1, POLB, TP53 |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 4.513E-05 | 3.927E-03 | AKR1B1, CYP1B1, MMP9, STAT6, TP53 |
| BP | GO:0050896; response to stimulus | GO:1901654; response to ketone | 4.527E-05 | 3.927E-03 | AKR1B1, AR, CD38, CFTR, CSNK2A1, PARP1 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 4.513E-05 | 3.927E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
| MF | GO:0005488; binding | GO:0001046; core promoter sequence-specific DNA binding | 5.371E-05 | 4.551E-03 | ESR1, ESR2, KMT2A, STAT6, TP53 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 5.785E-05 | 4.863E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.785E-05 | 4.863E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0051179; localization | GO:0034502; protein localization to chromosome | 6.192E-05 | 5.127E-03 | ESR1, HASPIN, TNKS, TNKS2 |
| BP | GO:0065007; biological regulation | GO:0044092; negative regulation of molecular function | 6.562E-05 | 5.332E-03 | ADORA2A, ADORA3, APP, CSNK2A1, CYP1B1, CYP2D6, ESR1, GSK3B, MAPT, MMP9, NFKB1, PTGS2, TNKS, TP53 |
| MF | GO:0005488; binding | GO:0019899; enzyme binding | 6.538E-05 | 5.332E-03 | ADORA2A, APP, AR, CFTR, CYP1A1, CYP1A2, CYP3A4, ESR1, ESR2, GSK3B, HIF1A, MAPT, PARP1, POLB, PTGS2, STAT6, SYK, TNKS2, TP53, USP2 |
| BP | GO:0008152; metabolic process | GO:0010557; positive regulation of macromolecule biosynthetic process | 7.013E-05 | 5.635E-03 | APP, AR, CD38, DYRK2, ESR1, ESR2, HIF1A, KMT2A, MMP12, NFKB1, NOX4, PARP1, STAT6, SYK, TNKS, TNKS2, TP53 |
| BP | GO:0009987; cellular process | GO:0010638; positive regulation of organelle organization | 7.158E-05 | 5.709E-03 | ALOX15, GSK3B, HIF1A, KMT2A, MAPT, MMP9, NOX4, TNKS, TNKS2, TP53 |
| BP | GO:0009987; cellular process | GO:0097237; cellular response to toxic substance | 7.461E-05 | 5.886E-03 | AKR1B1, CYP1B1, NFKB1, STAT6, TP53 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 7.663E-05 | 5.949E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 7.731E-05 | 5.949E-03 | TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 7.731E-05 | 5.949E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 7.731E-05 | 5.949E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 7.731E-05 | 5.949E-03 | CYP1A2, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0051090; regulation of DNA binding transcription factor activity | 7.851E-05 | 6.016E-03 | ADORA3, APP, AR, CYP1B1, ESR1, ESR2, NFKB1, SYK |
| BP | GO:0023052; signaling | GO:0050805; negative regulation of synaptic transmission | 8.528E-05 | 6.470E-03 | ACHE, ADORA1, CD38, PTGS2 |
| BP | GO:0023052; signaling | GO:0046887; positive regulation of hormone secretion | 9.054E-05 | 6.775E-03 | ADORA2A, CD38, CFTR, CYP19A1, HIF1A |
| BP | GO:0009987; cellular process | GO:0043410; positive regulation of MAPK cascade | 9.173E-05 | 6.840E-03 | ADORA1, ALOX15, APP, AR, FLT3, NOX4, SYK, THPO, XDH |
| BP | GO:0065007; biological regulation | GO:0050878; regulation of body fluid levels | 9.701E-05 | 7.160E-03 | ADORA1, ADORA2A, AKR1B1, ALOX12, CFTR, HIF1A, SYK, XDH |
| BP | GO:0008152; metabolic process | GO:0016125; sterol metabolic process | 1.013E-04 | 7.352E-03 | APP, CFTR, CYP19A1, CYP1B1, NPC1 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.072E-04 | 7.703E-03 | ADORA1, ADORA2A, CA2, CA7, NPSR1, PARP1 |
| BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 1.116E-04 | 7.917E-03 | APP, CDK6, GSK3B, HIF1A, MAPT, PARP1, PTGS2, SYK, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 1.116E-04 | 7.917E-03 | CYP19A1, CYP1A2, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0003950; NAD+ ADP-ribosyltransferase activity | 1.116E-04 | 7.917E-03 | PARP1, TNKS, TNKS2 |
| BP | GO:0040007; growth | GO:0040008; regulation of growth | 1.173E-04 | 8.267E-03 | ALOX12, APP, AR, CD38, CSNK2A1, ESR2, HIF1A, MAPT, TNKS2, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 1.253E-04 | 8.686E-03 | CYP1B1, HIF1A, PTGS2 |
| BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 1.253E-04 | 8.686E-03 | PARP1, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 1.253E-04 | 8.686E-03 | APP, GSK3B, PARP1 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 1.286E-04 | 8.775E-03 | ALOX12, ALOX15 |
| BP | Unclassified; | GO:0051534; negative regulation of NFAT protein import into nucleus | 1.286E-04 | 8.775E-03 | DYRK2, GSK3B |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.286E-04 | 8.775E-03 | CYP1A1, CYP3A4 |
| BP | GO:0032501; multicellular organismal process | GO:0032481; positive regulation of type I interferon production | 1.351E-04 | 9.136E-03 | MMP12, NFKB1, STAT6, SYK |
| BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 1.399E-04 | 9.317E-03 | CYP19A1, CYP3A4, ESR1 |
| MF | GO:0005488; binding | GO:0046983; protein dimerization activity | 1.445E-04 | 9.561E-03 | ABCG2, ACHE, ADORA1, ADORA2A, AR, FLT3, HIF1A, KMT2A, MAPT, NFKB1, PTGS2, TP53, TTR, XDH |
| BP | GO:0032502; developmental process | GO:0051094; positive regulation of developmental process | 1.519E-04 | 9.990E-03 | ALOX12, APP, AR, CA2, CYP1B1, HIF1A, LMNA, MAPT, NFKB1, PARP1, PTGS2, STAT6, SYK, THPO |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.079E-08 | 3.451E-06 | HSD17B1; ALOX5; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 5.180E-08 | 4.299E-06 | HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.281E-07 | 7.088E-06 | APP; CYP2D6; MAOA; ALOX5; ALOX15; ALOX12; PTGS2 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.165E-06 | 3.867E-05 | AR; GSK3B; CDK6; FLT3; MMP2; PTGS2; HIF1A; TP53; MMP9; NFKB1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 4.400E-06 | 1.217E-04 | MAOA; ALOX15; ADK; AKR1B1; ALOX12; PTGS2; CYP3A4; CYP19A1; HSD17B10; PKM; HSD17B1; ALOX5; CYP1A2; CYP1A1; CD38; XDH |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 5.673E-06 | 1.345E-04 | CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 3.164E-07 | 1.313E-05 | CA12; CA2; CA4; CA7 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.143E-05 | 2.109E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.006E-05 | 2.087E-04 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; PTGS2 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 1.860E-05 | 3.087E-04 | SYK; CSNK2A1; PARP1; PTGS2; NFKB1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 7.549E-05 | 9.062E-04 | GSK3B; SYK; CSNK2A1; CD38; TP53; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 8.188E-05 | 9.062E-04 | POLB; CDK6; PKM; SYK; TP53; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 7.993E-05 | 9.062E-04 | ABCC1; CDK6; CYP1B1; PTGS2; TP53; MMP9; NFKB1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 6.585E-05 | 9.062E-04 | ALOX5; ALOX15; ALOX12; PTGS2 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 6.339E-05 | 9.062E-04 | ABCC1; ADORA3; ADORA1; TP53; NFKB1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 8.930E-05 | 9.265E-04 | PKM; FLT3; TP53; HIF1A |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.147E-04 | 9.481E-04 | GSK3B; CDK6; CSNK2A1; TP53; NFKB1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.002E-04 | 9.481E-04 | MAOA; CYP2D6; CYP1A2; CYP3A4 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.183E-04 | 9.481E-04 | GSK3B; ESR1; NFKB1; ESR2 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.600E-04 | 1.154E-03 | CDK6; STAT6; TP53; MMP9; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.120E-04 | 9.481E-04 | CA2; CYP3A4; CFTR; ABCG2 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 2.685E-04 | 1.783E-03 | GSK3B; AR; TP53; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 2.354E-04 | 1.628E-03 | CDK6; PTGS2; TP53; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 4.032E-04 | 2.479E-03 | MMP2; ESR1; MMP9; ESR2 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 7.270E-04 | 3.893E-03 | MMP2; TP53; HIF1A; ESR1; MMP9 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 6.646E-04 | 3.677E-03 | ADORA2A; ADORA1; CFTR; NFKB1; TSHR |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 4.212E-04 | 2.497E-03 | KMT2A; FLT3; TP53; MMP9; NFKB1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 7.820E-04 | 4.056E-03 | GSK3B; TP53; ESR1; HIF1A |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.475E-03 | 7.199E-03 | PARP1; LMNA; TP53; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 2.863E-03 | 1.209E-02 | APP; GSK3B; MAPT; HSD17B10 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 3.979E-04 | 2.479E-03 | MMP2; MMP9; TP53 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 2.143E-03 | 9.362E-03 | GSK3B; SYK; NFKB1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 9.966E-04 | 5.013E-03 | ADORA1; PTGS2; TSHR |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.605E-03 | 7.399E-03 | CDK6; TP53; NFKB1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 6.852E-03 | 2.528E-02 | GSK3B; CDK6; SYK; TP53; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.143E-03 | 9.362E-03 | CDK6; TP53; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.535E-03 | 7.282E-03 | CYP1A2; CYP1A1; CYP3A4 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 6.783E-03 | 2.528E-02 | PTGS2; MMP9; NFKB1 |
| hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 3.643E-03 | 1.475E-02 | THPO; FLT3; CD38 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 8.611E-03 | 3.053E-02 | GSK3B; TP53; NFKB1 |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 4.649E-03 | 1.838E-02 | CA2; CD38; CFTR |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.406E-04 | 1.061E-03 | CYP1A2; ALOX15; CYP3A4 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.276E-02 | 4.077E-02 | POLB; GSK3B; TP53; NFKB1 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 4.906E-04 | 2.809E-03 | ABCC1; CFTR; ABCG2 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.138E-02 | 3.778E-02 | GSK3B; TP53; NFKB1 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 9.415E-03 | 3.256E-02 | GSK3B; CDK6; TP53 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.357E-02 | 4.249E-02 | GSK3B; CSNK2A1; TP53 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.617E-02 | 4.792E-02 | ADORA2A; ADORA3; ADORA1; TSHR |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.430E-02 | 4.397E-02 | GSK3B; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.646E-02 | 4.795E-02 | CDK6; TP53 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.703E-02 | 4.873E-02 | FLT3; NFKB1 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 1.591E-02 | 4.792E-02 | GSK3B; TP53 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.277E-02 | 4.077E-02 | MAOA; NFKB1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.132E-02 | 3.778E-02 | CYP3A4; XDH |
| hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 8.644E-03 | 3.053E-02 | PKM; GLO1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 5.944E-03 | 2.295E-02 | POLB; PARP1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.913E-03 | 1.209E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.199E-04 | 9.481E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; PTGS2; PTGS2; ABCC1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; SYK; SYK; ADORA2A; ADORA1; MMP12; PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; SYK; AKR1B1; PTGS2; PTGS2; PTGS2; PTGS2 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; ADORA1; XDH |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | SYK; HIF1A; TP53; FLT3; MMP9; PKM; MMP2 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; ADORA3; PTGS2 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; ADORA2A; ADORA1; ACHE; AKR1B1 |
| NA: NA | GIST | NA | FLT3 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ESR1 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PARP1 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; MMP12 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; PTGS2 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; NPSR1; APP |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA2A; ADORA1; MAOA; PTGS2; PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1 |
| C00-D49: Neoplasms | Melanoma | C43 | PARP1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; PARP1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| NA: NA | Male hypogonadism | NA | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; ADORA2A; MMP12; MMP12 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ESR1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| C00-D49: Neoplasms | Glioma | C71 | APP |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | CD38 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADORA1; ACHE; MAPT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; SYK; ADORA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; ACHE; ACHE; ACHE; MAOA; PTGS2; MAPT; APP |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | PARP1; MMP2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESR1; MMP2 |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ADORA2A; ADORA1; ACHE; MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; ADORA2A; ACHE; ADK; ESR1; PKM; PTGS2; PTGS2; PTGS2; PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; ESR1; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; MMP2; PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; TP53; CD38 |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; GSK3B; ADORA3; SYK; HIF1A; TP53; FLT3; FLT3; MMP9; NFKB1; ACHE; ESR1; ESR1; PARP1; MMP2; PTGS2; APP; CD38; CSNK2A1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; CYP2D6 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; PTGS2; ABCC1; ABCC1 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; SYK; MMP12; PTGS2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; PTGS2; PTGS2; PTGS2 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; ESR1; ESR1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; ADK |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; MAOA |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | GSK3B; ADORA1; AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; CYP3A4; MAOA |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; MMP9 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
| C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| NA: NA | Edema | NA | CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ADORA1; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |